Compare Abeona Therapeutics Inc (ABEO) vs iShares MSCI France ETF (EWQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs iShares MSCI France ETF — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while iShares MSCI France ETF trades at $44.82. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, iShares MSCI France ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | EWQ | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $7.23 | $48.35 |
52-Week Low | $4.17 | $41.43 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
EWQ trades at $46.07, up 0.33% today, with a bullish technical outlook from moving averages but neutral oscillators. Recent news highlights European equity strength and ECB rate hikes. Key support and resistance cluster at $46. A dividend of $1.09 is scheduled for June 2026.
Outlook is cautiously optimistic given technical momentum and European market tailwinds, but risks include geopolitical tensions and energy price volatility. The stock's performance is tied to broader European economic conditions and central bank policy shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About iShares MSCI France ETF
EWQ is a country-specific ETF that tracks the performance of the French equity market. It provides exposure to major global brands across sectors like luxury goods, industrials, and healthcare, including LVMH, Schneider Electric, and Hermes.
Read more on EWQ →
